Theriva Biologics, Inc. (TOVX)
USD 1.31
(1.5%)
USD 1.31
(1.5%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 60.21 Million USD | -16.21% |
| 2022 | 71.86 Million USD | 2.13% |
| 2021 | 70.36 Million USD | 736.68% |
| 2020 | 8.41 Million USD | -51.2% |
| 2019 | 17.23 Million USD | -42.82% |
| 2018 | 30.14 Million USD | 60.0% |
| 2017 | 18.83 Million USD | -16.27% |
| 2016 | 22.49 Million USD | -27.06% |
| 2015 | 30.84 Million USD | 61.12% |
| 2014 | 19.14 Million USD | 17.76% |
| 2013 | 16.25 Million USD | 21.11% |
| 2012 | 13.42 Million USD | 79.55% |
| 2011 | 7.47 Million USD | 81.85% |
| 2010 | 4.11 Million USD | 0.87% |
| 2009 | 4.07 Million USD | -44.81% |
| 2008 | 7.38 Million USD | -45.83% |
| 2007 | 13.63 Million USD | 8.93% |
| 2006 | 12.51 Million USD | 769.17% |
| 2005 | 1.43 Million USD | 0.0% |
| 2002 | 1.51 Million USD | -26.34% |
| 2001 | 2.05 Million USD | -62.27% |
| 2000 | 5.45 Million USD | 7.96% |
| 1999 | 5.04 Million USD | 74.09% |
| 1998 | 2.9 Million USD | 314.29% |
| 1997 | 700 Thousand USD | -75.0% |
| 1996 | 2.8 Million USD | 27.27% |
| 1995 | 2.2 Million USD | 450.0% |
| 1994 | 400 Thousand USD | -77.78% |
| 1993 | 1.8 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 42.39 Million USD | -13.01% |
| 2024 Q1 | 48.73 Million USD | -19.07% |
| 2023 Q4 | 60.21 Million USD | -2.17% |
| 2023 Q2 | 65.44 Million USD | -3.59% |
| 2023 Q3 | 61.54 Million USD | -5.96% |
| 2023 FY | 60.21 Million USD | -16.21% |
| 2023 Q1 | 67.88 Million USD | -5.53% |
| 2022 FY | 71.86 Million USD | 2.13% |
| 2022 Q1 | 88.99 Million USD | 26.48% |
| 2022 Q2 | 82.33 Million USD | -7.49% |
| 2022 Q3 | 78.69 Million USD | -4.42% |
| 2022 Q4 | 71.86 Million USD | -8.68% |
| 2021 Q4 | 70.36 Million USD | -6.33% |
| 2021 Q1 | 79.05 Million USD | 840.0% |
| 2021 Q2 | 77.25 Million USD | -2.28% |
| 2021 FY | 70.36 Million USD | 736.68% |
| 2021 Q3 | 75.12 Million USD | -2.76% |
| 2020 Q1 | 11.88 Million USD | -31.03% |
| 2020 Q4 | 8.41 Million USD | 16.76% |
| 2020 Q3 | 7.2 Million USD | -24.83% |
| 2020 Q2 | 9.58 Million USD | -19.39% |
| 2020 FY | 8.41 Million USD | -51.2% |
| 2019 Q3 | 20.74 Million USD | -13.57% |
| 2019 FY | 17.23 Million USD | -42.82% |
| 2019 Q4 | 17.23 Million USD | -16.91% |
| 2019 Q2 | 23.99 Million USD | -9.89% |
| 2019 Q1 | 26.63 Million USD | -11.64% |
| 2018 FY | 30.14 Million USD | 60.0% |
| 2018 Q4 | 30.14 Million USD | 179.19% |
| 2018 Q3 | 10.79 Million USD | 28.25% |
| 2018 Q2 | 8.41 Million USD | -32.48% |
| 2018 Q1 | 12.46 Million USD | -33.82% |
| 2017 Q1 | 17.71 Million USD | -21.24% |
| 2017 FY | 18.83 Million USD | -16.27% |
| 2017 Q2 | 15.74 Million USD | -11.17% |
| 2017 Q4 | 18.83 Million USD | -19.08% |
| 2017 Q3 | 23.27 Million USD | 47.9% |
| 2016 Q4 | 22.49 Million USD | 172.77% |
| 2016 Q2 | 16.33 Million USD | -28.19% |
| 2016 FY | 22.49 Million USD | -27.06% |
| 2016 Q1 | 22.74 Million USD | -26.27% |
| 2016 Q3 | 8.24 Million USD | -49.49% |
| 2015 Q4 | 30.84 Million USD | -27.65% |
| 2015 Q2 | 11.83 Million USD | -13.7% |
| 2015 Q1 | 13.71 Million USD | -28.35% |
| 2015 FY | 30.84 Million USD | 61.12% |
| 2015 Q3 | 42.63 Million USD | 260.18% |
| 2014 Q4 | 19.14 Million USD | 303.8% |
| 2014 Q3 | 4.74 Million USD | -48.96% |
| 2014 Q2 | 9.28 Million USD | -25.87% |
| 2014 Q1 | 12.53 Million USD | -22.92% |
| 2014 FY | 19.14 Million USD | 17.76% |
| 2013 FY | 16.25 Million USD | 21.11% |
| 2013 Q4 | 16.25 Million USD | 133.81% |
| 2013 Q3 | 6.95 Million USD | -27.78% |
| 2013 Q2 | 9.62 Million USD | -17.61% |
| 2013 Q1 | 11.68 Million USD | -12.96% |
| 2012 Q1 | 8.34 Million USD | 11.68% |
| 2012 FY | 13.42 Million USD | 79.55% |
| 2012 Q4 | 13.42 Million USD | 130.4% |
| 2012 Q3 | 5.82 Million USD | -19.59% |
| 2012 Q2 | 7.24 Million USD | -13.22% |
| 2011 Q1 | 7.2 Million USD | 75.28% |
| 2011 Q3 | 8.67 Million USD | -8.88% |
| 2011 FY | 7.47 Million USD | 81.85% |
| 2011 Q2 | 9.52 Million USD | 32.13% |
| 2011 Q4 | 7.47 Million USD | -13.82% |
| 2010 Q3 | 4.68 Million USD | 3.36% |
| 2010 Q4 | 4.11 Million USD | -12.17% |
| 2010 FY | 4.11 Million USD | 0.87% |
| 2010 Q1 | 3.27 Million USD | -19.68% |
| 2010 Q2 | 4.52 Million USD | 38.34% |
| 2009 Q3 | 5.07 Million USD | -11.48% |
| 2009 Q2 | 5.73 Million USD | -14.38% |
| 2009 Q1 | 6.69 Million USD | -9.33% |
| 2009 FY | 4.07 Million USD | -44.81% |
| 2009 Q4 | 4.07 Million USD | -19.7% |
| 2008 Q2 | 9.41 Million USD | -13.18% |
| 2008 Q4 | 7.38 Million USD | -10.0% |
| 2008 FY | 7.38 Million USD | -45.83% |
| 2008 Q1 | 10.84 Million USD | -20.48% |
| 2008 Q3 | 8.2 Million USD | -12.82% |
| 2007 FY | 13.63 Million USD | 8.93% |
| 2007 Q3 | 9.31 Million USD | -12.8% |
| 2007 Q4 | 13.63 Million USD | 46.31% |
| 2007 Q2 | 10.68 Million USD | -7.82% |
| 2007 Q1 | 11.59 Million USD | -7.37% |
| 2006 Q4 | 12.51 Million USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | 12.51 Million USD | 769.17% |
| 2005 FY | 1.43 Million USD | 0.0% |
| 2003 Q1 | 1.24 Million USD | -17.87% |
| 2002 Q3 | 1.79 Million USD | -21.83% |
| 2002 Q2 | 2.29 Million USD | -1.53% |
| 2002 FY | 1.51 Million USD | -26.34% |
| 2002 Q1 | 2.32 Million USD | 13.1% |
| 2002 Q4 | 1.51 Million USD | -15.39% |
| 2001 Q4 | 2.05 Million USD | -36.62% |
| 2001 Q3 | 3.24 Million USD | -7.36% |
| 2001 Q1 | 3.6 Million USD | -33.82% |
| 2001 FY | 2.05 Million USD | -62.27% |
| 2001 Q2 | 3.5 Million USD | -2.91% |
| 2000 Q4 | 5.45 Million USD | 57.2% |
| 2000 FY | 5.45 Million USD | 7.96% |
| 2000 Q3 | 3.46 Million USD | -11.98% |
| 2000 Q1 | 6.36 Million USD | 25.99% |
| 2000 Q2 | 3.93 Million USD | -38.07% |
| 1999 FY | 5.04 Million USD | 74.09% |
| 1999 Q1 | 2.3 Million USD | -20.69% |
| 1999 Q2 | 1.8 Million USD | -21.74% |
| 1999 Q3 | 1.6 Million USD | -11.11% |
| 1999 Q4 | 5.04 Million USD | 215.54% |
| 1998 FY | 2.9 Million USD | 314.29% |
| 1998 Q1 | 200 Thousand USD | -71.43% |
| 1998 Q4 | 2.9 Million USD | -6.45% |
| 1998 Q3 | 3.1 Million USD | -48.33% |
| 1998 Q2 | 6 Million USD | 2900.0% |
| 1997 FY | 700 Thousand USD | -75.0% |
| 1997 Q2 | 1.1 Million USD | -68.57% |
| 1997 Q3 | 1.3 Million USD | 18.18% |
| 1997 Q4 | 700 Thousand USD | -46.15% |
| 1997 Q1 | 3.5 Million USD | 25.0% |
| 1996 FY | 2.8 Million USD | 27.27% |
| 1996 Q4 | 2.8 Million USD | -39.13% |
| 1996 Q3 | 4.6 Million USD | -19.3% |
| 1996 Q2 | 5.7 Million USD | 128.0% |
| 1996 Q1 | 2.5 Million USD | 13.64% |
| 1995 FY | 2.2 Million USD | 450.0% |
| 1995 Q3 | 3.3 Million USD | 0.0% |
| 1995 Q4 | 2.2 Million USD | -33.33% |
| 1994 Q1 | 4.7 Million USD | 161.11% |
| 1994 Q4 | 400 Thousand USD | 0.0% |
| 1994 FY | 400 Thousand USD | -77.78% |
| 1993 Q1 | 5 Million USD | 0.0% |
| 1993 Q4 | 1.8 Million USD | -37.93% |
| 1993 Q2 | 4.4 Million USD | -12.0% |
| 1993 Q3 | 2.9 Million USD | -34.09% |
| 1993 FY | 1.8 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ADC Therapeutics SA | 354.78 Million USD | 83.029% |
| Alto Neuroscience, Inc. | 86.62 Million USD | 30.495% |
| Annovis Bio, Inc. | 10.2 Million USD | -489.826% |
| Biohaven Pharmaceutical Holding Company Ltd. | 513.21 Million USD | 88.268% |
| Ginkgo Bioworks Holdings, Inc. | 1.66 Billion USD | 96.384% |
| Nuvation Bio Inc. | 621.48 Million USD | 90.312% |
| Nuvation Bio Inc. | 621.48 Million USD | 90.312% |
| Arcus Biosciences, Inc. | 1.09 Billion USD | 94.501% |
| Zymeworks Inc. | 580.88 Million USD | 89.635% |